ABBV
AbbVie Inc.
NYSE · USD · Stock
$294.89
+31.60 (+12.00%)
past month
Closed- Market cap
- $521.11B
- P/E
- 50.67
- Yield
- 2.35%
- Volume
- 6.9M
- 52 weeks
- $191 – $299
- Dividend
About
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
AbbVie Inc. (ABBV) is a healthcare company listed on NYSE, traded in USD. Over the past year it moved between $190.75 and $298.74, and it pays a dividend every quarter.
- Healthcare
- Drug Manufacturers - General
- North Chicago, United States
- 57K employees
- Led by Robert A. Michael CPA
Coming up
Dividend paid
To owners on the ex-dividend day
Ex-dividend
$1.73 per share last time
Financials
Revenue, last 12 months
$66.01B+10.30%
Earnings
Beat the estimate
3 of 4 quarters
Q4 2025
+2.16%
Q1 2026
-0.77%
Q2 2026
+1.15%
Q3 2026
+1.32%
Earnings per share, last 12 months $5.82
Analysts
27 analysts say
Buy
12-month target$283.19-3.97%
Dividends
Yield · per share, yearly
2.35%$6.92
Ownership
- Institutions
- 77.39%
- Insiders
- 0.11%
Prices from Yahoo Finance, may be delayed